Pediatrix Medical Group, Inc. $MD Stock: SummerHaven Investment Management LLC Increases Holdings

Key Points

• SummerHaven Investment Management increased its Pediatrix Medical Group stake by 92.7% in the third quarter, reaching 111,299 shares valued at approximately $2.86 million. Institutional investors collectively own 97.71% of the company.
• Analyst sentiment remains cautious: one analyst rates the stock Buy and five rate it Hold, producing a consensus rating of Hold and an average price target of $26.60. Some firms recently raised their targets to $28.
• Pediatrix reported stronger-than-expected quarterly results, with EPS of $0.63 versus the $0.59 estimate and revenue of $487.78 million. Revenue increased 4.1% year over year, while shares recently traded at $27.32.

SummerHaven Investment Management LLC grew its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 92.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 111,299 shares of the company's stock after acquiring an additional 53,534 shares during the period. Pediatrix Medical Group comprises about 2.0% of SummerHaven Investment Management LLC's portfolio, making the stock its 5th largest holding. SummerHaven Investment Management LLC owned 0.14% of Pediatrix Medical Group worth $2,864,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Pediatrix Medical Group in the second quarter worth about $347,383,000. Wasatch Advisors LP purchased a new position in shares of Pediatrix Medical Group in the first quarter worth approximately $43,861,000. Bank of New York Mellon Corp acquired a new stake in shares of Pediatrix Medical Group during the second quarter valued at approximately $14,297,000. Rockefeller Capital Management L.P. raised its holdings in shares of Pediatrix Medical Group by 814.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 594,351 shares of the company's stock valued at $12,713,000 after acquiring an additional 529,367 shares during the period. Finally, Empowered Funds LLC purchased a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at approximately $12,668,000. 97.71% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Weiss Ratings upgraded shares of Pediatrix Medical Group from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, September 9th. Truist Financial lifted their price objective on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a "hold" rating in a research report on Tuesday, July 14th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a $25.00 price objective on shares of Pediatrix Medical Group in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Pediatrix Medical Group from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 13th. Finally, UBS Group increased their target price on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a "neutral" rating in a report on Thursday, August 6th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $26.60.

Pediatrix Medical Group Trading Down 1.6%

Shares of NYSE MD opened at $27.32 on Friday. Pediatrix Medical Group, Inc. has a one year low of $16.02 and a one year high of $28.02. The firm has a market capitalization of $2.22 billion, a PE ratio of 13.07 and a beta of 0.61. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.45. The business has a 50-day moving average price of $26.45 and a two-hundred day moving average price of $24.70.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. The company had revenue of $487.78 million for the quarter, compared to analysts' expectations of $478.49 million. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%. The business's revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.53 EPS. As a group, analysts predict that Pediatrix Medical Group, Inc. will post 2.17 earnings per share for the current fiscal year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc provides physician-led health care services to hospitals, health systems and patients across the United States. The company focuses on specialized care for women, infants and children, supporting patients in hospital-based and affiliated clinical settings.

Its services include neonatal and perinatal care, maternal-fetal medicine, pediatric cardiology and other pediatric subspecialties. Pediatrix physicians commonly practice in neonatal intensive care units, delivery rooms, pediatric emergency departments and other hospital departments, working with care teams to manage complex medical needs.

The company was founded in 1979 and operated for many years under the name MEDNAX, Inc It adopted the Pediatrix Medical Group name in 2023 as part of a broader effort to emphasize its pediatric, neonatal and maternal-fetal health care businesses.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pediatrix Medical Group, Inc. (NYSE:MD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.